Perspective Therapeutics, Inc. · AMEX:CATX
Perspective Therapeutics — Investor Presentation (April 2026)
52 slides from Perspective Therapeutics's investor presentation, Apr 20, 2026
Slide 1: Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Redefining Oncology Treatment with Next-Generation Radiopharmaceuticals
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “s
Slide 3: Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology
Why Radiotherapy, Why Perspective: Realizing the Untapped Value Across Oncology
Slide 4: Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Rapidly Advancing Best-in-Class Next Generation Radiopharmaceuticals
Slide 5: Proprietary Radioligand Platform Optimizes Therapeutic Index
Proprietary Radioligand Platform Optimizes Therapeutic Index
Slide 6: Proprietary Pb-Based Chelator Designed for Broader and Safer Use
Proprietary Pb-Based Chelator Designed for Broader and Safer Use
Slide 7: Lead-212: Optimal Isotope with Advantages Over Beta and Other Alpha Emitters
Lead-212: Optimal Isotope with Advantages Over Beta and Other Alpha Emitters
Slide 8: Imaging Optimizes Targeted Delivery to Tumor
Imaging Optimizes Targeted Delivery to Tumor
Slide 9: * Phage display followed by
| _ i : | [ 1 of 1 * Phage display followed by affinity maturation * Bioconjugate chemistry and further optimization * In vitro and in vivo binding assays identified lead candidates? | : Ta) PERSPECTIVE
Slide 10: Solid Tumors are an Attractive Market for Radiopharmaceuticals
Solid Tumors are an Attractive Market for Radiopharmaceuticals
Slide 11: End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway
End-to-End Manufacturing with Clinical Supply Secured and Commercial Scale Underway
Slide 12: Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio
Advancing a Diverse Wholly Owned 212Pb-Based Oncology Portfolio
Slide 13: SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
SSTR2+ Neuroendocrine Tumors is a Large, Growing Market with Significant Unmet Need
Slide 14: VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
VMT-⍺-NET: Potential First-in-Class 212Pb-Radioligand Therapy Targeting SSTR2
Slide 15: Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs
Ongoing Phase 1/2a to Establish Broad Therapeutic Window For VMT-⍺-NET in NETs
Slide 16: Compelling Anti-tumor Activity with Sustained or Deepening Responses
Compelling Anti-tumor Activity with Sustained or Deepening Responses
Slide 17: VMT-⍺-NET: Durable Disease Control Across All Doses
VMT-⍺-NET: Durable Disease Control Across All Doses
Slide 18: Best-in-class Safety Profile
Best-in-class Safety Profile1
Slide 19: VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level
VMT-α-NET’s Compelling Profile Supports Potential Registration Study at Current Dose Level
Slide 20: Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind
Checkpoint Inhibitors Transformed Care of Melanoma but Leave Many Patients Behind
Slide 21: VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
VMT01: Potential First-in-Class 212Pb Therapy Targeting MC1R for Melanoma
Slide 22: Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma
Ongoing Phase 1/2a Open-Label Trial For VMT01 in Melanoma
Slide 23: Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01
Preliminary Anti-tumor Activity Observed at Lower Dose of VMT01
Slide 24: Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 2 Patients)
Treatment Emergent Adverse Events (All Grades, Occurring in ≥ 2 Patients)
Slide 25: VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development
VMT01 is Well-tolerated with Initial Anti-tumor Activity Supporting Further Development
Slide 26: FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential
FAP-ɑ is an Attractive Cancer Target with Broad Solid Tumor Potential
Slide 27: PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors
PSV359: Potential First-in-Class 212Pb Therapy Targeting FAP-ɑ for Solid Tumors
Slide 28: Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors
Ongoing Open-label Phase 1/2a Trial For PSV359 in Advanced Solid Tumors
Slide 29: PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent
PSV359 has Improved Tumor Retention, Highlighting its Potential as a Therapeutic Agent
Slide 30: Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain
Strong IP Portfolio Covering All Aspects of Radiopharmaceutical Value Chain
Slide 31: Strong financial position
Strong financial position Funding into late 2027 Cash, cash equivalents and short-term investments as of December 31, 2025 ~$145 million Share count as of December 31, 2025 ~74.3 million Outstanding common stock warrants & options as of December 31, 2025 ~10.9 million On February 3, 2026, we complet
Slide 32: Phase 1/2 Data Expected Across All Clinical Programs in 26
Phase 1/2 Data Expected Across All 3 Clinical Programs in 2026
Slide 33: Slide 33
Slide 34: Abbreviations
Abbreviations AACR: American Association for Cancer Research AE: adverse event ALP: alkaline phosphatase ALT: alanine transaminase ASCO: American Society of Clinical Oncology ASCO-GI: ASCO Gastrointestinal Cancers Symposium AST: aspartate aminotransferase AUC: area under the curve CR: complete respo
Slide 35: APPENDIX
APPENDIX
Slide 36: Deeply Experienced Management Team in Radiopharmaceuticals and Drug Development
Deeply Experienced Management Team in Radiopharmaceuticals and Drug Development 20+ years of exper ein biotechnology companies; public and private companies; ‘oncology and nuclear pharmacy Thijs Spoor Chief Executive Officer - cotynia Srsiswio TEE verify.» Vewront ror Aa om BD An accomplished financ
Slide 37: NETs Trials
NETs Trials Study NETTER-12 Randomized 2:1 (+/-octreotide) N=229 Status Supported registration Dose Level 4x QBW | 200 mCi (administered) Patient Population Prior PRRT Median time from dx ORR AEs (>20%) Grade 3+ (>10%) (CR/PR) 277Lu-DOTATATE 177Lu-DOTATATE 377Lu-EDOTREOTIDE® 212pb-DOTAMTATE® 225\c-D
Slide 38: VMT-⍺-NET: Baseline Patient Characteristics in AACR 2026 Data Analysis
VMT-⍺-NET: Baseline Patient Characteristics in AACR 2026 Data Analysis
Slide 39: Patient Exposure and Follow-up with [212Pb]VMT-α-NET in AACR 2026 Data Analysis
Patient Exposure and Follow-up with [212Pb]VMT-α-NET in AACR 2026 Data Analysis
Slide 40: Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment
Patient with Confirmed PR After [212Pb]VMT-α-NET Treatment
Slide 41: Blood Creatinine During Follow-up for All Patients Treated (n=64)
Blood Creatinine During Follow-up for All Patients Treated (n=64)
Slide 42: Refractory Metastatic Melanoma Trials
Refractory Metastatic Melanoma Trials
Slide 43: ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma
ICI Combo Rationale: Strong Synergy with [212Pb]VMT01 in Melanoma
Slide 44: Regional Manufacturing Allows Commercialization of 212Pb-labeled Finished Products
Regional Manufacturing Allows Commercialization of 2!2Pb-labeled Finished Products The “network effect” designed to ensure reliable commercial supply for ready-to-administer therapeutics Population Sites Today | 2027-81 2029 Radius “11 hrs Coralville, IA ic) Clinical Supply Somerset, NJ 1c) 75m Chic
Slide 45: Daily production at regional sites ensures supply of ready-to-administer product
Daily production at regional sites ensures supply of ready-to-administer product
Slide 46: Strong intellectual property portfolio
Strong intellectual property portfolio Perspective-owned/Exclusively-licensed IP 18 Issued Patents (full patent term expires 2036-2044, with potential PTE) * Composition of matter for radiopharmaceutical compounds targeting SSTR2, FAP-a, and MC1R * System and methods for generating Pb-212 radionucli
Slide 47: Perspective’s proprietary chelator has been optimized for lead-based RPTs
Perspective’s proprietary chelator has been optimized for lead-based RPTs
Slide 48: Construct designed for better clinical outcome
Construct designed for better clinical outcome
Slide 49: Construct designed for better clinical outcome
Construct designed for better clinical outcome
Slide 50: 212Pb Isotope Decay Chain and Importance of the Pb-specific Chelator
212Pb Isotope Decay Chain and Importance of the Pb-specific Chelator Thorium Where the drug goes = where the 1sy alpha particle is deposited @) OH 2 Bj Bismuth 61m * Perspective’s proprietary chelator retains ~95% of 2128] after transition in drug formulation? * Generic chelators leak the 2?2Bi alph
Slide 51: 225Ac Isotope Decay Chain and Potential for Off-target Toxicity
225\c Isotope Decay Chain and Potential for Off-target Toxicity Isotope Supply Production Therapy Bismuth 46m | A¥P1KO] 32310 1-440 404 [eHUDIOg Alpha-particle emission OH imparts sufficient “recoil” fe) energy to break chemical aN s~¢ bonds N O o = Target Organs @ Liver @) Kidneys @) ‘ay PERSPECTIV
Slide 52: 212Pb hits tumors hard and fast and disappears
212Pb hits tumors hard and fast and disappears 212Pb is a “high dose rate” alpha emitter with a short half life — energy is deposited rapidly to tumor and then gone Comparative al Particle Decay Over Time! 52 Comparative alpha decays Delivering alphas faster while drug and isotope tumor retention is
Perspective Therapeutics — Investor Presentation (April 2026) on 6ix